Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

HD

HDFC Pharma and Healthcare Fund - Growth Option

HDFC Mutual Fund · Equity · Sectoral/ Thematic

₹21.97

+0.06 (+0.25%)

AUM: —

NAV updated 18 days ago

Option

Growth

Risk

Very High

Sharpe Ratio

2.16

Std Dev (1Y)

12.83%

Historical Returns (CAGR)

Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.

1m

+2.42%

3m

+11.9%

6m

+26.44%

1y

+26.77%

3y

—

5y

—

10y

—

since inception

+30.95%

TopFund's Take on HDFC Pharma and Healthcare Fund - Growth Option

HDFC Pharma and Healthcare Fund - Growth Option is a Sectoral/ Thematic fund from HDFC Mutual Fund.

Cost: Expense ratio data for this fund isn't available yet.

Risk-adjusted performance: Over the trailing 1-year period, the fund shows a strong Sharpe ratio of 2.16 — the fund has generated solid returns relative to the volatility it exposed investors to. Separately, annualised volatility of 12.83% is fairly typical for Sectoral/ Thematic funds.

Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.

This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.

Sector Allocation

Sector allocation not available yet.

Asset Allocation

Asset allocation not available yet.

Fund Snapshot

Scheme Code 152084
ISIN INF179KC1HL7
NAV Date 09 Sep 2026
Status Active

Frequently Asked Questions about HDFC Pharma and Healthcare Fund - Growth Option

* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.